What is a potential risk of using long-acting beta-agonists alone in asthma treatment?

The use of long-acting beta-agonists (LABAs) as a standalone treatment for asthma is associated with an increased risk of severe asthma exacerbations. LABAs are effective bronchodilators that help to relax the muscles of the airways, providing relief from symptoms. However, when used without an inhaled corticosteroid (ICS), there is a risk that they may mask inflammation and lead to the worsening of asthma control.

Inhaled corticosteroids are crucial in addressing the underlying inflammation in asthma, which is a significant aspect of the condition. Without the anti-inflammatory effects of ICS, patients relying solely on LABAs may experience a temporary relief of symptoms while the inflammation remains untreated. This discrepancy can set the stage for more severe exacerbations, as the underlying condition is not being adequately managed.

The other options presented do not accurately reflect the realities of using LABAs alone. While LABAs do contribute to bronchodilation, they do not improve overall lung function in the absence of an anti-inflammatory component. Furthermore, stating that there are "no risks associated with their use" or that LABAs lead to "better control of symptoms" when used alone is misleading since it overlooks the potential exacerbation risks inherent in such a treatment approach.